Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Myotonic Dystrophy Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Myotonic Dystrophy Overview | 9 | 1 |
| Pipeline Products for Myotonic Dystrophy Comparative Analysis | 10 | 1 |
| Myotonic Dystrophy Therapeutics under Development by Companies | 11 | 1 |
| Myotonic Dystrophy Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Myotonic Dystrophy Pipeline Products Glance | 13 | 2 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Myotonic Dystrophy Products under Development by Companies | 15 | 1 |
| Myotonic Dystrophy Products under Investigation by Universities/Institutes | 16 | 1 |
| Myotonic Dystrophy Companies Involved in Therapeutics Development | 17 | 7 |
| AMO Pharma Limited | 17 | 1 |
| BioMarin Pharmaceutical Inc. | 18 | 1 |
| F. Hoffmann-La Roche Ltd. | 19 | 1 |
| Ionis Pharmaceuticals, Inc. | 20 | 1 |
| Marina Biotech, Inc. | 21 | 1 |
| Sarepta Therapeutics, Inc. | 22 | 1 |
| WAVE Life Sciences Ltd. | 23 | 1 |
| Myotonic Dystrophy Therapeutics Assessment | 24 | 9 |
| Assessment by Monotherapy Products | 24 | 1 |
| Assessment by Target | 25 | 2 |
| Assessment by Mechanism of Action | 27 | 2 |
| Assessment by Route of Administration | 29 | 2 |
| Assessment by Molecule Type | 31 | 2 |
| Drug Profiles | 33 | 22 |
| Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy Drug Profile | 33 | 1 |
| Antisense RNAi Oligonucleotides for Myotonic Dystrophy Drug Profile | 34 | 1 |
| IONISDMPK-2.5Rx Drug Profile | 35 | 1 |
| IUCT-169 Drug Profile | 36 | 1 |
| IUCT-290 Drug Profile | 37 | 1 |
| IUCT-309 Drug Profile | 38 | 1 |
| LR-08 Drug Profile | 39 | 1 |
| mexiletine hydrochloride Drug Profile | 40 | 1 |
| Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy Drug Profile | 41 | 1 |
| Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy Drug Profile | 42 | 1 |
| PRO-135 Drug Profile | 43 | 1 |
| RP-33 Drug Profile | 44 | 1 |
| Small Molecule to Target CUG RNA for Myotonic Dystrophy 1 Drug Profile | 45 | 1 |
| Small Molecule to Target RNA for Myotonic Dystrophy Drug Profile | 46 | 1 |
| Small Molecules for Myotonic Dystrophy Drug Profile | 47 | 1 |
| Small Molecules for Myotonic Dystrophy Type 1 Drug Profile | 48 | 1 |
| Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I Drug Profile | 49 | 1 |
| Small Molecules to Target RNA for Myotonic Dystrophy Drug Profile | 50 | 1 |
| SRT-149 Drug Profile | 51 | 1 |
| SRT-152 Drug Profile | 52 | 1 |
| tideglusib Drug Profile | 53 | 1 |
| VAL-0411 Drug Profile | 54 | 1 |
| Myotonic Dystrophy Dormant Projects | 55 | 1 |
| Myotonic Dystrophy Discontinued Products | 56 | 1 |
| Myotonic Dystrophy Product Development Milestones | 57 | 2 |
| Featured News &Press Releases | 57 | 1 |
| Sep 19, 2013: AmorChem invests in the development of a therapeutic to treat myotonic dystrophy | 57 | 1 |
| Dec 20, 2012: Scripps Florida Scientists Create New Approach to Destroy Disease-Associated RNAs in Cells | 57 | 2 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |